

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




364

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68		A1	(11) International Publication Number: WO 99/07894 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/US98/16347 (22) International Filing Date: 5 August 1998 (05.08.98) (30) Priority Data: 08/906,443 5 August 1997 (05.08.97) US (71) Applicant (for all designated States except US): WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street, Madison, WI 53705 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KOLESAR, Jill, M. [US/US]; 8074 Burr Oak Trail, Cross Plains, WI 53528 (US). ALLEN, Peter, G. [US/US]; Apartment F, 2525 University Avenue, Madison, WI 53705 (US). (74) Agent: DONOVAN, Paul, F.; Michael Best & Friedrich LLP, 100 East Wisconsin Avenue, Milwaukee, WI 53202-4108 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: DIRECT QUANTITATION OF LOW COPY NUMBER RNA



(57) Abstract

A direct quantitation of RNA contained in a sample is obtained by capillary electrophoresis of the RNA hybridized to a DNA probe of complementary sequence stabilized by the combination of a fluorophore terminally conjugated to the DNA probe and a dye intercalating the RNA-DNA hybrid so formed. The RNA is quantified by measuring the total fluorescence emitted by the electrophoresed hybrid upon excitation by a laser generated light beam. DNA/DNA hybrids may also be detected by this method.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DIRECT QUANTITATION OF LOW COPY NUMBER RNA

5

FIELD OF THE INVENTION

This invention relates to the field of direct nucleic acid detection, particularly RNA in low copy number, without a requirement for amplification of either the number of RNA molecules, or by amplification of a detection signal. The method further utilizes capillary electrophoresis to detect a target RNA-DNA probe hybrid band. The invention also combines laser-induced fluorescence and capillary electrophoresis.

BACKGROUND OF THE INVENTION

The quantitation of RNA, particularly RNA derived from infectious agents or from cellular sources, is important in the diagnosis and monitoring of disease states caused by such agents. For example, the viral load detected in serum correlates to high concentrations of virus in the lymph nodes and has predictive value in assessing progression of AIDS to advanced stages, as reported in Ho, et al., *Nature*, 373: 123 (1995) and Mellors, et al., *Ann. Intern. Med.*, 122: 573 (1996). Viral titers in serum are also correlated with disease progression for other viruses such as HCV, nonA nonB hepatitis other than HCV, and atypical lentiviruses.

There are several fundamental problems in RNA quantitation in low copy number. If there are too few molecules to detect by conventional means, amplification of the target sequence to increase its numbers by several logs is necessary. However, the coefficients of variability (CV) may often exceed 20 percent or more, so that the result obtained is

-2-

unreliable, and does not correlate with the stage of disease. The coefficient of variability (CV) is defined as the standard deviation of the values obtained divided by the mean. Increased signal from a small number of target molecules is another approach, but the final result depends upon a large number of reactions which must occur in correct sequence. Again, there is a large CV because of reaction sequence errors giving a spectrum of values.

Alternatively, direct measurement of the low RNA copy number in the native sample, even where adequate detection sensitivities can be achieved, is thwarted by the inherent instability of RNA-DNA duplexes. Increasing the length of the hybridized target can increase both sensitivity and stability of the hybrid, but the additional nucleotide sequence combinations increase the chance of nonspecific hybridizing to fragments of host nucleic acids or partial hybridization to nonselected regions of the viral genome, thereby contributing to a falsely inflated positive value. Most of the improvements to date in low RNA copy number quantitation represent attempts to better control the multiple molecular events involved in signal or nucleic acid amplification strategies.

The three main amplification systems currently available include branched chain signal amplification (bDNA), reverse transcriptase polymerase chain reaction (RT-PCR), and nucleic acid sequence based amplification (NASBA). The strategy of the first two, bDNA and RT-PCR, involves using a first reaction step that converts the system from an RNA target to a DNA target.

In bDNA an initial probe hybridizing with a complementary probe contains a plurality of noncomplementary sites capable of hybridizing to further DNA strands, which in turn may hybridize sites noncomplementary to the probe sequence, so that as repeated layers of hybridization occur, a branched DNA structure of extreme complexity is created. The last

-3-

to be annealed strand in the branched structure carries a reporter. Thus the original RNA target molecule gives rise to an amplification of the signal generating capability of the system. A full explanation and description of the bDNA technique is set forth in 5 Fultz, et al., "Quantitation of plasma HIV-I RNA using an ultra sensitive branched DNA (bDNA) assay", in *Program and Abstracts of the 2nd National Conference on Human Retroviruses* (1995), and product literature, L-10 6170 Rev. 5.0 for the Quantiplex™ HIV-RNA Assay (Chiron Corporation).

In RT-PCR a cDNA is generated from the RNA template, and then an ordinary PCR amplification ensues utilizing selected primers to define the left and right 15 ends of the amplicon. Each successive round of synthesis and denaturation causes an exponential increase in the number of progeny strands generated in the system. After the amplification is complete, a probe having a complementary sequence to some portion 20 of the amplicon and carrying a reporter can be used for detecting the amplified target. In both RT-PCR and bDNA, the original RNA target can theoretically be dispensed with, without impairing the sensitivity of the test, once the conversion to a DNA system has 25 occurred. These methods effectively get around the inherent lability of the RNA target or its RNA-DNA duplex hybrid.

Similarly, both RT-PCR and bDNA share many of the same deficiencies. Both systems rely upon the 30 integrity of a large number of successive hybridization events. If an early hybridization event fails, for any of a number of reasons such as structural (steric) hindrance, uncorrected mismatch, binding of a defective enzyme molecule, etc., the final number of copies, and 35 therefore the intensity of the signal will be ablated. These random occurrences help to account for the great sensitivity of the assays coupled with a widely variable coefficient of variability. The commercial

-4-

form of the test normalizes variability by co-amplification of an internal standard. To control for variability the internal standard must be amplified under identical conditions as the target yet be able to be differentiated from the target, an almost impossible task. Also, introducing an internal standard changes the PCR reaction kinetics itself. RT-PCR, while showing some efficacy, is in practice very labor intensive, and not practical under normal clinical laboratory conditions.

In NASBA, the lability of RNA is overcome by increasing copy number to a vast number. The technique involves creating a cDNA from the target RNA and then generating a large number of transcripts from bDNA template, which in turn can be converted to a cDNA, and so on. The number of transcripts produced is always much greater than the number converted to cDNA, so that a large excess of RNA occurs. The process is initiated upon annealing of two primers, one of which contains a phage promoter, which in the ensuing cDNA provides a point of initiation for transcription. Unlike PCR where the numbers of actual cycles of amplification are nominally controlled by the number of temperature cycles, there is much less control in NASBA. The technique suffers from a lack of uniformity as between different target sequences, and in the same target sequence from one run to another. The commercial form of the assay employs three internal calibrators, which are co-amplified with the target sequence. In any detection technique it is desirable for the analytical coefficient of variability (CV) to be less than 15 percent.

The three techniques were recently compared in a study by Coste, et al., *J. Med. Virol.*, 50: 293 (1996). bDNA was found to be most reproducible with CVs ranging from 6-35 percent. Better results were achieved at high copy number, 12.4% vs. 31% for low copy number. However, sensitivity was only 68 percent with a lower

-5-

level of detection at 4000 HIV equivalents. NASBA was the least reliable test with CVs ranging from 13-62 percent, with CV averages of 20.7 percent for high copy number and 41.8 percent for low copy number.

5 Sensitivity was 100 percent with a lower level of detection at 2600 HIV equivalents. Finally, RT-PCR has a sensitivity of 93 percent, but a mean CV of 43 percent.

10 While improvements in the foregoing techniques may result from optimization of the operating conditions of the assays, and from discovery of reagent combinations that minimize interferences with hybridizations, it is unlikely that variability will ever be reduced uniformly to coefficient values less than 15 percent.

15 This is because priming errors and hybridization interferences cannot be entirely overcome, and misevents occurring early in the sequence of amplification steps have a geometric impact on the result. Thus the wide range of CV. If the level of

20 sensitivity for direct detection of RNA could be increased by several orders of magnitude over standard UV detection methods, and the problem of RNA-DNA duplex instability be solved, direct detection would provide a viable alternative to current amplification-based

25 methods without loss of reliability.

SUMMARY OF THE INVENTION

30 In the method of the present invention, two different dye molecules are utilized to produce a characteristic signal emission upon excitation with a laser beam. RNA is extracted from a cell-free biological specimen such as serum or from a cellular

35 RNA source, hybridized to a fluorescent DNA probe (first dye molecule covalently attached to probe) of complementary sequence to form an RNA-DNA hybrid, applied as the hybrid RNA-DNA duplex to a capillary

-6-

electrophoresis column, electrophoresing in a hybrid band in the presence of an intercalating dye (second dye in electrophoresis buffer), and quantitatively detecting the amount of RNA-DNA hybrid by measuring the
5 total fluorescent intensity of light emitted from the hybrid band upon excitation by laser-induced fluorescence, and decay of the excited molecules to light of a longer wave length.

In capillary electrophoresis, the sample
10 containing the RNA-DNA hybrid is loaded onto the gel column and an electric current is applied to the gel matrix. The dye which permeates the gel matrix, is capable of intercalating the hybrid, and binds to the interstices of the duplex, so that these intercalated
15 molecules migrate with the hybrid band. The unbound dye molecules are not seen as background because its quantum yield varies in the presence of nucleic acid. The band is quantitated by directing a scanning laser-induction beam along the gel. The hybrids with pendant
20 dye (both covalently attached and bound by electrostatic interaction), migrating as a band, absorb the light of excitation wavelength, and emit at a lower energy wavelength. Peak areas of light emission intensity are identified. The total fluorescence is
25 the sum of the fluorescence values under the peak.

Applicants have discovered that the configuration of terminal labelling of the DNA probe with one dye type, and allowing intercalating of the duplex hybrid by a second dye type has the unexpected benefit of
30 dramatically increasing the stability of the hybrid. Hence, the present invention provides a method for stabilizing during capillary electrophoresis nucleic acid hybrids consisting of an RNA strand and a fluorophore terminally labelled DNA strand of short
35 length (15 to about 40 base pairs in length) which involves only electrophoresing the nucleic acid hybrid in the presence of an intercalating dye. Any dye, preferably which fluoresces at the same wavelength as

-7-

the dye covalently attached to the DNA probe, capable of intercalating double stranded nucleic acids will be efficacious in increasing stability. The ability to stabilize short RNA-DNA duplexes means that an RNA target sequence can now readily be selected having less than 5 percent homology to any other portion of the target, and non-homology to host nucleic acids, as verified by a GenBank search or by comparison to other published sequence databases.

The principles of the invention are also applicable to DNA detection by visualizing DNA/DNA hybrids. The technique has particular efficacy for detecting and quantitating target wild type and mutant DNA sequences containing mutations associated with oncogene and tumor suppressor markers such as K-ras, DPC4, DCKNZ, and p53. The steps in the technique are essentially the same.

The present invention also provides a kit containing the key ingredients for carrying out a direct quantitative test for HIV-1 and other targets suspected of being present in a biological specimen utilizing capillary electrophoresis and laser-induced fluorescence. The kit contains a quantity of a DNA probe of 15 to 30 nucleotides labelled with a fluorophore at its 3',5' terminus, or at both termini, whose sequence is complementary to an RNA sequence having less than 5% homology to any other sequence of commensurate length contained within the target gene, or other host genome. The kit also provides a quantity of a fluorescent dye capable of intercalating an RNA-DNA hybrid molecule of 15-30 base pairs. The vessels containing the reagent probe and dye are made of materials to which the reagents do not adhere, such as surface-treated borosilicate glass, polypropylene and the like, and are shaped to accommodate an automatic pipetter tip.

The methods and reagents of the present invention fulfill the following advantages and objectives:

-8-

--fast and highly reliable direct assay for
quantitative determination of RNA

--a low coefficient of variability even at low
copy number of RNA

5 --lower cost than amplification-based tests

 --greater sensitivity than any other direct gene
quantitation method.

BRIEF DESCRIPTION OF THE DRAWINGS

10

Figures 1A-1C are electropherograms of cellular
RNA (1.856 $\mu\text{g}/\mu\text{L}$) obtained from *Spodoptera frugiperda*
culture. Figure 1A represents an injection at time 0.
A second injection of same sample after 30 minutes at
15 room temperature is shown in Figure 1B. Figure 1C
shows a third injection of same sample after 60 minutes
at room temperature.

Figure 2 is an electropherogram analysis of
fluorescently labeled HIV specific probe alone diluted
20 in DEPC treated water to a concentration of 72 fg/7.1
nL, which elutes at 11 min.

Figures 3A-3C show an electropherogram analysis of
hybridization products. RNA samples obtained from a
HIV seropositive patient and a seronegative volunteer
25 were hybridized with a HIV specific probe and analyzed
as described in experimental. Figure 3A represents a
HIV RNA/Probe complex elutes at 12 min, indicating the
presence of HIV RNA in the patient's serum. Figure 3B
represents a seronegative volunteer. Figure 3C is a
30 negative control containing all reaction components
except RNA.

Figures 4A and 4B show electropherogram analysis
of DNA/DNA hybridization products. Figure 4A is the
control showing migration of the probe at 8-9 minutes.
35 Figure 4B shows the DNA/DNA hybrid peak migrating at
about 11.5 minutes.

-9-

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

A basic problem in direct gene quantitation which Applicants have overcome is the extreme lability of target RNA-DNA duplexes under conditions of electrophoresis. Interestingly, the use of carrier RNA to stabilize the target RNA and the double stranded nucleic acid of the hybrid, is unavailing. Experiments utilizing carrier RNA, as set forth in Example 3, Table 4, show that there is no stabilization of the RNA-DNA hybrid having the sequence of Seq. I.D. No. 1 in the presence of carrier. Normally, carrier nucleic acid or protein, in the case of proteinaceous targets, function as a coprecipitant, or compete for a degradative enzyme, thereby protecting the target species through shear overwhelming numbers. Failure of carrier RNA to mitigate degradation of the hybrid is consistent with the conclusion that the RNA-DNA hybrid of short length is inherently unstable, and its lability is not due to a contaminating nuclease, or other process for which a carrier population can exert protection or rescue. Since the lability appears to be activated by the electric current, separation of tRNA from duplex may cause a loss of whatever protection might otherwise be afforded.

Isolating RNA from biological specimens may be carried out by any conventional method which takes precautions in minimizing RNA degradation. Accordingly, procedures involving heat or strong acid/base reagents are to be avoided. In preparing specimens from serum, blood is centrifuged to remove cells, and then extracted. There are several extraction kits commercially available for this purpose, as, for example, the Ultraspec II RNA isolation system from Biotex.

The probe sequence is selected for uniqueness within the genome of the organism to be detected and monitored, and which is unlikely to show any homology

-10-

for the host genome. This is important because it is impossible to guarantee that all cells contained in the specimen will be removed by centrifugation. The degree of homology between the probe sequence and the remainder of the target genome should be as low as possible, but less than 5 percent. Thus, it is important to select a sequence long enough to confer selectivity and short enough to avoid partial homologies with non-target RNAs.

The DNA probe will have a nucleotide sequence of about 15 to 50 bases, preferably between 20 and 30 bases. In the case of HIV-1, a unique, genetically stable 26 base sequence from the pol gene was selected, having the sequence 5'-ACAGTATTAGAAGAYATGRRTTTGCC-3' (Seq. I.D. No. 1) (in which Y = A or C; and R = A or G). This sequence is identified in GenBank as entry U62632. A probe terminally labelled with a fluorophore at the 5' end and having the sequence given above which is complementary to the HIV-1 sense strand was prepared synthetically utilizing 5'-fluorescein phosphoramidite. Another sequence of interest in HIV quantitation is: 5'-GGCAAARRCATYTCTTCTAATACTGT-3' (Seq. I.D. No. 2). Also, the following sequences are useful in the present invention for quantitation of Quinone Acceptor Oxidoreductase and Human Topoisomerase I, respectively.

NAD(P)H:

5' -TCGGACCTCTATGCCATGAACT-3'	Seq. I.D. No. 3
5' -AGTTCATGGCATAGAGGTCCGA-3'	Seq. I.D. No. 4
5' -AGGCTGGTTTGAGCGAGTGTTC-3'	Seq. I.D. No. 5
5' -GAACACTCGCTCAAACCAGCCT-3'	Seq. I.D. No. 6
5' -CAGCAGACGCCCCGAATTCAAAT-3'	Seq. I.D. No. 7
5' -ATTTGAATTTCGGGCGTCTGCTG-3'	Seq. I.D. No. 8

Human Topoisomerase I:

5' -AGAGACCTCGAGATGAGGATGA-3'	Seq. I.D. No. 9
5' -TCATCCTCATCTCGAGGTCTCT-3'	Seq. I.D. No. 10
5' -TCTCGTATTTCTGCCAGTCCTT-3'	Seq. I.D. No. 11
5' -AAGGACTGGCAGAAATACGAGA-3'	Seq. I.D. No. 12

-11-

Applicants sought to utilize an intercalating fluorescent dye to visualize a band of probed RNA migrating on an electrophoresis column. It was found, however, that for short (15-30) base pairs neither a fluorescein labelled DNA probed RNA duplex without
5 intercalating dye, or a non-terminally labeled DNA probed RNA duplex in the presence of an intercalating dye alone was stable during electrophoresis. However, the combination of a terminally fluorophore labeled DNA
10 probe and the presence of an intercalating fluorescent dye produced remarkable stability of the duplex, for reasons not yet understood.

The preferred terminal fluorophore is fluorescein, although others such as rhodamine, or the BODIPY series
15 (Molecular Probes, Inc.) may be utilized also. The preferred intercalating dye is thiazole orange, although other dyes such as YOYO (also available from Molecular Probes, Inc., and whose structure is given at p.155 of its 1996 Catalogue for Product No. Y-3601) may
20 be used. When using a laser-induced detection system, it is preferable from a sensitivity standpoint, to use terminating and intercalating dye pairs which emit light at the same wavelength, thereby boosting the signal additively, see Table 3. Fluorescein and
25 thiazole orange absorb at 488nm and emit at 520nm. For probe manufacture, fluorescein is ideal because of its ease of use, well known coupling chemistries, and its low cost. Thiazole orange is more expensive, but in the capillary mode of electrophoresis, the small
30 volumes reduce usage. In an alternate embodiment of the present method, the intercalating dye may be taken up by the DNA-RNA hybrid prior to loading on the gel.

Utilizing the combined dyes prevents degradation of the RNA-DNA hybrid, and also increases sensitivity
35 to levels comparable to other methods. The most sensitive assay system will be the best system for monitoring HIV, and with a lower detection limit of 50 ag this system is more sensitive than other available

-12-

methods. The lower limit of the linear range is 11 picograms to 72 femtograms, which provides a lower detection limit of 7200 HIV equivalents per ml compared to 10,000 equivalents for bDNA. The greater sensitivity of RT-PCR (350 equivalents/ml) has a precision of only 11-93 percent, whereas in the present method of direct detection, the CV is always less than 15 percent for peak area (total fluorescence). The precision (CV) of peak position in the gel (lapsed time) is less than 1 percent. In hybridization assays of actual patient specimens producing RNA-DNA hybrids, reliable and quantitative detection of less than 2000 equivalents of HIV could be achieved.

The technique of capillary electrophoresis (CE) is utilized in the present method. A discussion of methods applicable to the Beckman instrument used in the experiments set forth in the Examples is given in Altria, et al., *Quantitative Applications of Capillary Electrophoresis in Pharmaceutical Analysis*, Beckman:1994, Publication No. 538703, and Altria, *Capillary Electrophoresis Guidebook*, Humana Press: 1995. CE has been applied to direct quantitation of HIV-1 in patients having high serum levels of HIV-1. Fernandez-Arcas, et al., *J. Acq. Immune Defic. and Hum. Retrobiol.*, 12: 107 (1996) reported detection by direct UV analysis of extracted RNA at levels of greater than 10^8 virions/ml correlated to the very high levels of circulating virus in early infection. This direct technique, even with the enhancement expected with laser-induced fluorescence is not sensitive enough to monitor anti-HIV drug therapy where levels of circulating virus decline. For further comprehensive materials on conventional methods and applications of capillary electrophoresis, please see Landers, *Handbook of Capillary Electrophoresis*, CRC Press: 1997.

Other advantages of the present invention will be apparent from the Examples which follow.

-13-

EXAMPLE 1

Sample Collection and RNA Extraction. RNA was obtained from a HIV seropositive patient by centrifugation of whole blood at 3,000 xg for 15 min at 4°C on a Centra GP8R (International Equipment Corporation, Needham Heights, MA, USA) refrigerated centrifuge. The plasma was separated and stored at -80°C. RNA was extracted from plasma samples using the Ultraspec II RNA isolation system (Biotex, Houston, TX, USA) as recommended by the manufacturer. RNA was extracted from both plasma and peripheral blood lymphocytes of a HIV seronegative normal volunteer. RNA was also obtained from *Spodoptera frugiperda* 21, grown in TC-100 serum (HyClone, Logan, UT, USA) at 27°C. RNA was resuspended in DEPC treated water (Biotex, Houston, TX, USA) and quantitated spectrophotometrically.

Probe Synthesis and Hybridization. To ensure specificity, a unique gene sequence is probed. The pol region is the most genetically unique of the HIV genome and a 26 bp sequence in this region was selected (GenBank entry U62632). Uniqueness was verified by a GenBank search. A 5'-fluorescein phosphoramidite (Glenn Research, Sterling, VA, USA) (probe sequence = 5'-ACAGTATTAGAAGAYATGRRTTGGCC-3') labeled DNA probe for this sequence was synthesized by the University of Wisconsin Biotechnology Center (Madison, WI, USA). Sample RNA present in a concentration of 0.095 µg/µL was diluted serially with DEPC treated water and hybridized with the DNA probe (1.0125 µg) in a buffer volume of 30 µL containing 10 mM Tris-HCl (pH 7.2), 1 mM EDTA (pH 8.0), 50 mM NaCl, and 1 mM cetyltrimethylammonium bromide (CTAB) (ACROS, Pittsburgh, PA, USA). The mixture was heated at 85°C for 10 min, and then incubated at 42°C for 4 h. The addition of CTAB to the hybridization, as reported by Pontius, et al., *Proc. Natl. Acad. Sci.*, 88:8237 (1991).

-14-

Following incubation, samples were digested for 30 min at 37°C with RNAase One (4.5 U) (Promega Corporation, Madison, WI, USA) in a digestion buffer of 50 μ L consisting of 50 mM Tris-HCl (pH 7.2), 5 mM EDTA (pH 8.0). Samples were flash frozen at -80°C to stop enzymatic digestion.

EXAMPLE 2

10 CE-LIF Analysis. Separations were performed on a P/ACE 2050 CE system (Beckman Instruments, Fullerton, CA, USA) with the temperature held constant at 20°C. Detection of hybridization samples was achieved using laser-induced fluorescence in the reversed-polarity
15 mode (anode at the detector side) at excitation of 488 nm and emission of 520 nm. Samples were introduced hydrodynamically by 10 s injections at 0.34 Pa across a 65 cm X 100 μ m coated eCAP dsDNA capillary filled with replaced linear polyacrylamide (Beckman Instruments,
20 Fullerton, CA, USA). The capillary was conditioned with eCAP dsDNA 1000 gel buffer which contained 60 μ L of LiFluor dsDNA 1000 EnhanceCE (thiazole orange) intercalator per 20 mL (Beckman Instruments, Fullerton, CA, USA). Separation were performed under constant
25 voltage at 7.0 kV for 15-30 min. The capillary was rinsed with gel buffer for 3 min prior to each injection. The capillary was calibrated with the fluorescently labeled probe and a mixture of RNA molecular markers (Ambion, Austin, TX, USA). The 5
30 markers ranged in size from 100-500 bp. Postrun analysis of data was performed using the System Gold chromatography data system (Beckman Instruments, Fullerton, CA, USA).

-15-

Referring to Table 1, the stabilities of various calibrator RNA standards is given. The low CV percentages indicate that CE is highly precise with respect to variation both in terms of total
 5 fluorescence (peak area) and migration time on the gel.

Table 1: Stability of Cellular RNA at Room Temperature

Peak Area						
10	<u>Peak Injection</u>	5S	16S	18S	23S	28S
	Time 0	1523	2891	586	2717	921
	Time 30 min	1277	2605	650	2368	1002
	Time 60 min	1371	2603	598	2183	911
15	Mean	1390.33	2699.67	611.33	2422.67	944.67
	St dev	124.13	165.70	34.02	271.1	49.9
	CV%	8.9	6.1	5.5	11	5
	% change over 30 min	-17	-10	+10	-13	-8
20	% change over 60 min	-10	-10	+2	-20	-1
Migration Time						
	<u>Injection</u>					
	Time 0	11.96	12.17	13.45	14.58	16.68
25	Time 30 min	11.94	12.21	13.44	14.54	16.64
	Time 60 min	11.94	12.20	13.45	14.55	16.66
	Mean	11.95	12.19	13.45	14.56	16.66
	St dev	0.012	0.021	0.006	0.021	0.02
	CV%	0.1	0.1	0.04	0.1	0.1
30						

-16-

Table 2 compares the detection limits and reproducibility for duplex combination of RNA/RNA, RNA/DNA, and DNA/DNA. The lower detection limit for DNA/DNA is explained by the greater known number of dye molecules intercalating that duplex than for RNA/RNA. All CV values were less than 15 percent.

Table 2: Comparison of Detection Limits and Reproducibility of Various Nucleotide Complexes

	Minimum Detectable Quantity			Precision	
	Nucleotide Complex	Weight	HIV equivalents	Migration Time CV%	Peak Area CV%
15	RNA/RNA	500 fg	50,000	0.16-1.1	0.9-1.0
	DNA/DNA-Fluorescein	36 ag	4	0.18-0.22	7.3-11
20	DNA/RNA-Fluorescein	190 ag	21	0.18-0.22	5.6-7.3

-17-

Table 3 shows that the total fluorescence when both a terminal dye and an intercalating dye are used is additive when emission takes place at the same wavelength. The low panel shows the dramatic contribution to duplex stability of the dye combination.

Table 3

1. Synergy

Experiment:

DNA/DNA hybrids

Dye	Peak Area (rounded to nearest 10,000 rfu)
FL alone	90,000
TO alone	10,000
FL+TO	100,000

2. Stability

Experiment

DNA/RNA hybrids

Complex	Degradation (% decrease in peak area)	Retention time CV
FL+TO	<5%	<0.5%
FL	41-45%	>70%
TO	31-33%	1%

EXAMPLE 3

Analysis of Low Copy HIV RNA by Addition of Carrier RNA. Serum obtained from HIV seropositive patient #31

-18-

was serially diluted with sterile double distilled H₂O. The original sample contained 5×10^5 HIV copies per ml and five dilutions were made, the most dilute containing 10 copies of HIV RNA per ml.

5 E. Coli tRNA (100 mcg) was added to the diluted samples, and the hybridizations to labelled probe were carried out.

RNA was then extracted by Ultraspec II RNA Isolation System, hybridized as usual and analyzed by
10 CE-LIF.

Table 4

	Copies HIV per ml serum	Weight equivalent	Peak Area (ND = not detectable)
15	5×10^5	50 pcg	9768
	10^5	10 pcg	2437
	10^4	1 pcg	ND
	10^3	100 fmg	ND
	10^2	10 fmg	ND
20	10	1 fmg	ND

The failure to detect viral RNA at higher dilutions indicates that the hybrids are unstable, even in the
25 presence of carrier tRNA. Contrast this to extracting RNA then serially diluting. Detection limits are 1.9 fg for DNA/RNA complexes.

EXAMPLE 4

30

Direct Detection of DNA. Direct detection method for the analysis of DNA can also be demonstrated. Genomic DNA is extracted by standard techniques and digested with Mbo I to generate smaller and more easily workable
35 fragments of DNA. The target DNA is then hybridized

-19-

with a gene specific probe. This hybridization product generates a DNA/DNA probe. A typical probe in use is much small (26mer) than the target fragment of DNA generated by Mbo I restriction nuclease (420bp), so
5 while it may be detected, the assay at this point is not highly quantitative and the migration time is somewhat variable.

DNA amplified by conventional PCR may contain mutations introduced by PCR. Thus direct detection by
10 the present invention eliminates a source of false outcomes, which is very important for mutation analysis. Figure 4B illustrates detection of a hybrid DNA/DNA peak migration at 11.5 minutes. Figure 4A is a control showing only a predominant peak at 8-9 minutes
15 for the unhybridized probe.

-20-

CLAIMS

What is claimed is:

- 5 1. A method for direct quantitation of an RNA sequence present in a sample in low copy number comprising
 - extracting the RNA from a biological specimen
 - hybridizing said RNA to a fluorescent DNA probe
 - 10 having a complementary sequence to said RNA to form a RNA-DNA hybrid
 - applying said RNA-DNA hybrid to a capillary electrophoresis column
 - electrophoresing said hybrid in a band under an
 - 15 electric current applied to said capillary column in the presence of a dye capable of intercalating double stranded nucleic acids, and
 - quantitatively detecting said RNA-DNA hybrid by measuring the total fluorescent intensity of light
 - 20 emitted from said hybrid band upon excitation by laser-induced fluorescence.
2. A method for direct quantitation of an RNA sequence present in a sample comprising
 - 25 extracting the RNA from a biological specimen
 - hybridizing said RNA to a fluorescent DNA probe having a complementary sequence to said RNA to form an RNA-DNA hybrid
 - loading said RNA-DNA hybrid onto a capillary
 - 30 electrophoresis column having a matrix containing a dye capable of intercalating double stranded nucleic acids
 - applying an electric current through the matrix of said column to effect electrophoresis of said RNA-DNA hybrid in a hybrid band, and
 - 35 quantitatively detecting said RNA-DNA hybrid by measuring the total fluorescence of light emitted from said hybrid band upon excitation by laser-induced fluorescence.

-21-


3. A method for direct quantitation of an DNA sequence present in a sample in low copy number comprising

- 5 extracting the DNA from a biological specimen
hybridizing said DNA to a fluorescent DNA probe
having a complementary sequence to said RNA to form a DNA-DNA hybrid
applying said DNA-DNA hybrid to a capillary
10 electrophoresis column
electrophoresing said hybrid in a band under an electric current applied to said capillary column in the presence of a dye capable of intercalating double stranded nucleic acids, and
15 detecting said DNA-DNA hybrid by measuring the total fluorescent intensity of light emitted from said hybrid band upon excitation by laser-induced fluorescence.

- 20 4. A method for direct quantitation of an DNA sequence present in a sample comprising
extracting the DNA from a biological specimen
hybridizing said DNA to a fluorescent DNA probe
having a complementary sequence to said RNA to form an
25 DNA-DNA hybrid
loading said DNA-DNA hybrid onto a capillary electrophoresis column having a matrix containing a dye capable of intercalating double stranded nucleic acids
applying an electric current through the matrix of
30 said column to effect electrophoresis of said DNA-DNA hybrid in a hybrid band, and
quantitatively detecting said DNA-DNA hybrid by measuring the total fluorescence of light emitted from said hybrid band upon excitation by laser-induced
35 fluorescence.

-22-

5. A method for stabilizing during capillary electrophoresis nucleic acid hybrids consisting of an RNA strand and a fluorophore terminally labelled DNA strand 15 to 40 base pairs in length comprising
5 electrophoresing said nucleic acid hybrids in the presence of a dye capable of intercalating double stranded nucleic acids.
6. A kit for conducting a direct quantitative test
10 for HIV-1 suspected of being present in a biological specimen utilizing capillary electrophoresis and laser-induced fluorescence comprising
a DNA probe of 15 to 30 nucleotides terminally
labelled with a fluorophore at the 5' end and having a
15 sequence complementary to a target RNA sense sequence having less than 5% homology to any other sequence of commensurate length contained within the structural gene and host genome as verified by comparison to published databases, and
20 a dye capable of intercalating an RNA-DNA hybrid molecule of 15-30 base pairs.
7. The kit of claim 4 wherein said RNA sequence is an RNA strand conforming to Seq. I.D. Nos. 1-12.
25
8. The method of claims 1 or 2 wherein said RNA sequence is a portion of the sequence encoding the HIV-1 genome.
9. The method of claim 1 or 2 wherein said RNA
30 sequence is a 25 base sense strand segment conforming to Seq. I.D. No. 1.
10. The method of claims 1, 2 or 3 wherein said dye is
35 selected from the group consisting of thiazole orange and YoYo.



2/9




FIG. 1B

3/9




FIG. 1C






FIG. 2








FIG. 3C




FIG. 4A




FIG. 4B

-1-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Kolesar, Jill M.
Allen, Peter G.

(ii) TITLE OF INVENTION: DIRECT QUANTITATION OF LOW COPY
NUMBER RNA

(iii) NUMBER OF SEQUENCES: 12

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Kent Barta
(B) STREET: 100 East Wisconsin Ave.
(C) CITY: Milwaukee
(D) STATE: WI
(E) COUNTRY: USA
(F) ZIP: 53202

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) PRIORITY APPLICATION:

(A) COUNTRY: U.S.
(B) SERIAL NUMBER: 08/906443
(C) DATE: 5 August 1997 (05.08.97)

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Barta, Kent S.
(B) REGISTRATION NUMBER: 29,042
(C) REFERENCE/DOCKET NUMBER: 96429/9005

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 608/2573501
(B) TELEFAX: 608/2832275

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

-2-

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACAGTATTAG AAGAMATGRR TTTGCC

26

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GGCAAARRCA TMTCTTCTAA TACTGT

26

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TCGGACCTCT ATGCCATGAA CT

22

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

-3-

AGTTCATGGC ATAGAGGTCC GA

22

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AGGCTGGTTT GAGCGAGTGT TC

22

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GAACACTCGC TCAAACCAGC CT

22

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

-4-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CAGCAGACGC CCGAATTCAA AT

22

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATTTGAATTC GGGCGTCTGC TG

22

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AGAGACCTCG AGATGAGGAT GA

22

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

-5-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TCATCCTCAT CTCGAGGTCT CT

22

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TCTCGTATTT CTGCCAGTCC TT

22

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AAGGACTGGC AGAAATACGA GA

22

INTERNATIONAL SEARCH REPORT

In tional Application No
PCT/US 98/16347

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE WPI Section Ch, Week 9131 Derwent Publications Ltd., London, GB; Class B04, AN 91-227685 XP002084014 & JP 03 147797 A (SHIMADZU CORP) , 24 June 1991 see abstract	1-10
Y	--- SCHWARTZ H E ET AL: "CAPILLARY ELECTROPHORESIS WITH LASER-INDUCED FLUORESCENCE DETECTION OF PCR FRAGMENTS USING THIAZOLE ORANGE" ANALYTICAL CHEMISTRY, vol. 64, no. 15, 1 August 1992, pages 1737-1740, XP000297441 see the whole document --- -/--	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

11 November 1998

Date of mailing of the international search report

27/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

INTERNATIONAL SEARCH REPORT

In tional Application No

PCT/US 98/16347

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>BIANCHI N. ET AL.,: "Capillary electrophoresis: detection of hybridization between synthetic oligonucleotides and HIV-1 genomic DNA amplified by polymerase-chain reaction" J. VIROL. METHODS, vol. 47, - 1994 pages 321-329, XP002084004 see the whole document ---</p>	1-10
Y	<p>WO 93 13223 A (CHIRON CORP) 8 July 1993 see whole doc. and esp claim 1 ---</p>	1-10
A	<p>EP 0 714 986 A (TOSOH CORP) 5 June 1996 see claims and example 9 page 13 ---</p>	1-10
A	<p>FANG C. ET AL.,: "Sequence-dependent separation of DNA fragments by capillary electrophoresis in the presence of SYBR Green I" BIOTECHNIQUES, vol. 23, - July 1997 pages 58-60, XP002084005 see the whole document ---</p>	1-10
P,X	<p>KOLESAR J.M. ET AL.,: "Direct quantification of HIV-1 RNA by capillary electrophoresis with laser-induced fluorescence" J. CHROMAT., vol. 697, - 12 September 1997 pages 189-194, XP002083988 see the whole document -----</p>	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/16347

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9313223 A	08-07-1993	EP 0726962 A JP 7502654 T	21-08-1996 23-03-1995
EP 0714986 A	05-06-1996	JP 8211050 A US 5814447 A	20-08-1996 29-09-1998